CV Sciences (CVSI) Total Debt Growth (1y) (2016 - 2026)
CV Sciences (CVSI) Total Debt Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.86 Bn | 42.90 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.54 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.46 Bn | 29.79 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.57 Bn | 22.77 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.71 Bn | 11.18 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 41.53% |
| 10 | CV Sciences | 4.10 Mn | 3.84 Mn | 1.45 Mn | -98.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -98.54% |
| Mar 31, 2026 | -94.32% |
| Dec 31, 2025 | 143.57% |
| Dec 31, 2022 | 123.74% |
| Mar 31, 2022 | 375.21% |
| Mar 31, 2018 | 63.25% |
| Dec 31, 2017 | 171.50% |
| Sep 30, 2017 | -56.33% |
| Jun 30, 2017 | -41.59% |
| Mar 31, 2017 | -11.38% |
| Dec 31, 2016 | 222.06% |